急性早幼粒细胞白血病治疗的进展

 自从应用全反式维A酸（ATRA）和砷剂（ATO）治疗急性早幼粒细胞白血病（APL）以来，APL疗效有了显著提高。初治与复发APL的完全缓解率达80 % ~ 90 %。对APL病理特征的分子遗传学认识的提高为治疗干预提供了理论的基础。近年来为延长无病生存期（DFS）进行了大量的研究，特别在APL新治疗方案和靶向治疗的策略以及新制剂方面的研究，取得良好的结果。

Progress on the treatment of acute promylocytic leukemia

Since the introduction of all-trans retinoic acid (ATRA) and arsenic trioxid into the treatment of acute promylocytic leukemia (APL), the effect of treatment of APL have been dramatically improved. The CR(complete remission) rate of new diagnosis and relapsed APL were 80 % ~ 90 %. An increased understanding of molecular genetics of the pathologic features of APL has provided a rational basis for therapeutic intervention. Recently, in order to prolong disease free survival (DFS), a numbers of trials have been done. The excellent outcomes has reported on new therapeutic project for APL induce remission,consolidation and maintenance phase, the new strategy of targeted therapy and new agents.